--- a
+++ b/clusters/9knumclustersv2/clust_1102.txt
@@ -0,0 +1,70 @@
+Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
+No other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study
+Concurrent use of other investigational agents
+Patients may not be receiving any other concurrent investigational agents, or have received any investigational agent within four weeks of commencing this protocol.
+Concurrent therapy with any other investigational drug
+Patients may not receive any concurrent investigational agents while on study
+Concurrent use of any other investigational agents
+Patients who are receiving concurrent investigational therapy;
+Concurrent administration of any other investigational agents
+Subject receiving concurrent chemotherapeutics or investigational agents within  days of study entry, including gliadel wafers or gliasite application.
+Concurrent administration of other cancer specific therapy or investigational agents during the course of this study is not allowed
+Concurrent treatment with any other investigational therapeutic agents
+No other concurrent chemotherapeutic or investigational agents for this cancer. However, concurrent glucocorticoids are allowed;
+Receiving concurrent investigational therapy
+No other concurrent investigational agents are allowed
+Concurrent use of other investigational agents
+Patients receiving concurrent investigational chemotherapeutic agents
+Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents).
+Patients receiving any concurrent investigational agents
+Concurrent use of restricted agents
+Concurrent enrollment on another investigational therapy
+Concurrent use of other investigational agents or Optune device
+Concurrent use of investigational therapeutic agent
+Concurrent use of any other investigational agents
+Concurrent use of investigational therapeutic agent
+Subjects may not be receiving any other investigational agents; concurrent enrollment in another clinical investigational drug or device study is prohibited
+Concurrent use of any other investigational agents
+The use of other concurrent investigational agents will not be allowed
+Concurrent use of other investigational agents
+Concurrent use of any other investigational agents
+Patients receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapy
+Concurrent administration of any other investigational agents
+Patients who are receiving any other concurrent investigational agents (patients are eligible to enroll  weeks after completion of prior agent)
+Concurrent treatment with other investigational agents is not permitted
+Concurrent therapy with any other investigational drug
+Concurrent use of other investigational agents.
+Concurrent treatment with other investigational drugs.
+Patients may not receive any other concurrent investigational agents while on study
+Concurrent treatment with other investigational agents
+Concurrent anti-cancer treatment in another investigational trial
+Concurrent use of investigational therapeutic agent
+Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents) other than temozolomide
+Concurrent use of any other investigational agents.
+Use of investigational agents or concurrent anti-cancer treatment within the last  weeks of registration
+Other concurrent investigational agents;
+Concurrent therapy with other investigational agents
+Concurrent anti-cancer treatment in another investigational trial
+Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)
+Concurrent use of other investigational agents
+Concurrent therapy with any other investigational agent
+ANY concurrent investigational agents
+No concurrent methotrexate, thiotepa, cytarabine, or investigational agents
+Concurrent use of other investigational agents and patients who have received investigational drugs =<  weeks prior to enrollment
+Concurrent treatment with other investigational agents(s)
+No other concurrent investigational treatment
+Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents, radiation or immunotherapy) within  weeks of the first dose of the study drug
+Concurrent use of any other investigational agents on a clinical trial
+No other concurrent investigational agents
+Patients who are receiving any other investigational agents with the intent to treat myeloma; permitted concurrent therapies include:\r\n* Bisphosphonates
+Concurrent use of other investigational agent
+Patient is receiving concurrent treatment with other investigational agents not allowed as part of the combination regimen in the parental study protocol.
+Concurrent enrollment in another investigational clinical study
+Patients receiving concurrent investigational drugs
+Concurrent investigational drugs
+Concurrent use of investigational agents
+Concurrent use of investigational therapeutic agent
+Concurrent use of investigational therapeutic agent
+Concurrent therapy with an investigational agent
+Concurrent therapy with investigational agents
+Concurrent systemic therapy for prostate cancer with investigational agents.